Navigation Links
The ETICS Project, Led by CYTOO in Collaboration With Cellectis bioresearch and the CEA, to Receive Euro 7.6 Million in Funding From OSEO
Date:9/26/2011

PARIS, Sept. 26, 2011 /PRNewswire/ -- CYTOO, a company that specializes in cell-based assays (Grenoble, France), has joined up with Cellectis bioresearch, the specialist in genome customization and commercial subsidiary of Cellectis (Alternext: ALCLS), and the CEA, the French Alternative Energies and Atomic Energy Commission, to develop new high-value cell-based assays for drug development and toxicology.

The project, named ETICS(1), will focus on the development of cell-based assays, which will be commercialized as kits, comprising cells genetically modified by Cellectis bioresearch and CYTOO's micropatterned supports. By controlling the expression, the architecture and the 2D and 3D environment of the cells, thus mimicking in vivo conditions of the tissue they derive from (liver, heart...), these assays will have much higher relevance to discover better and safer drugs.

OSEO, the French agency financing innovation, is providing euro 7.6 million in funding for the ETICS project for the next 5 years, including euro 4 million for CYTOO, euro 2.9 million for Cellectis bioresearch and euro 0.7 million for the CEA. This project could generate over euro 600 million for the consortium in ten years.

"The three partners of the ETICS project have complementary know-how and synergies in the key domains necessary for the success of such a project," said Francois Chatelain, Chairman and CEO of CYTOO.

"This funding will enable us to extend our product offering and to gain market share from our major North American competitors," stated Marc Le Bozec, Cellectis bioresearch CEO. "I would like to congratulate the ETICS partners and OSEO teams for the quality of work accomplished, which we believe will yield an important advancement in the development of new drugs."

About the "Industrial Strategic Innovation" Program from OSEO

The "Industrial Strategic Innovation" (ISI) program supports the emergence of
'/>"/>

SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Genetics Determine Optimal Drug Dose of Common Anticoagulant
4. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
5. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
6. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
7. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
8. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
9. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
10. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
11. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... The nuclear imaging market is estimated to ... of 12.08%. Nuclear medicine is the use of radioisotopes ... of Nuclear imaging used commonly are PET and SPECT. ... nuclear medicine applications like nuclear cardiology procedures. However, the ... shortage of molybdenum-99 isotope which is in turn will ...
(Date:6/1/2015)... , June 1, 2015 ... weight over large area and improve the quality life ... ulcer. These devices play a significant role in inhibiting ... reduce the need to turn or rotate an immobile ... include mattress, mattresses overlay, and specialty beds. These devices ...
(Date:6/1/2015)... MECHANICSBURG, Pa. , June 1, 2015 ... announced that MJ Acquisition Corporation, a joint venture that ... Stowe XII, L.P., has completed its previously announced acquisition ... in the new joint venture. About ... leading operator of specialty hospitals and outpatient rehabilitation clinics ...
Breaking Medicine Technology:North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 2North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 3Global Pressure Relief Devices Market 2015-2019 2Global Pressure Relief Devices Market 2015-2019 3Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 2Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 3
... /PRNewswire-FirstCall/ -- La Jolla,Pharmaceutical Company today announced updated ... of Riquent(R) (abetimus,sodium), its drug candidate for systemic ... the previous,conclusion that there is a definitive and ... and 900 mg doses of Riquent compared,with placebo ...
... Calando,Pharmaceuticals, a leading siRNA therapeutics company and ... announced the publication in the Proceedings of ... journal of the,NAS, of the first non-human ... Calando's lead siRNA therapeutic candidate that is ...
Cached Medicine Technology:La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 2Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 3Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 4Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 5
(Date:6/2/2015)... June 02, 2015 Each year, Cosmetic ... Choice Beauty Awards. This year, the organization’s members – ... winner of the QVC® Beauty Quest Award at the ... Micro Emulsion (ME) Technology and 2-in-1 approach to skincare ... noting the brand’s loyal consumer and professional fan bases, ...
(Date:6/2/2015)... Join us for a new event in Westwood, New Jersey—the ... , who overcame her brain aneurysm during the summer of ... awareness and funds for brain aneurysm research. , Rhonda ... will be one less case of someone suffering from a ... the 1st Anniversary Awareness Walk in Honor of Rhonda ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Specialty ... audit, compliance and risk solutions , and Radar ... risk management effectiveness gap-improvement program. , All organizations ... uncertainty on objectives. Organizations not only assess and ... capabilities to do this (risk managing) thereby embedding ...
(Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... Lynn Lester as a 2015-2016 inductee into ... recognized with this prestigious distinction for leadership in business. ... professional women, boasting more than 700,000 members and over ... Lynn Lester with this prestigious award,” said NAPW President ...
(Date:6/1/2015)... 02, 2015 The National Association ... as a 2015-2016 inductee into its VIP Professional ... this prestigious distinction for leadership in safety, environment, health ... organization exclusively for professional women, boasting more than 700,000 ... pleased to present Lourinda with this important honor,” said ...
Breaking Medicine News(10 mins):Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2Health News:New Awareness Raising Event in Westwood, NJ to Benefit Renowned Brain Aneurysm Foundation 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2
... interdisciplinary team of researchers at Brigham and Women,s ... Sciences and Technology has demonstrated a better way to ... engineered nanoparticles that can inhibit a signaling pathway and ... area. Details of their work appear on April 20, ...
... Lincare Holdings Inc. (Nasdaq: LNCR ), a ... to patients in the home, today announced financial results for ... March 31, 2009, net revenues were $371.7 million, compared with ... 2008. Net income for the quarter ended March 31, ...
... April 20 Amgen (Nasdaq: AMGN ) today ... results on Thursday, April 23, 2009 after the close of ... conference call with the investment community at 2 p.m. Pacific ... Kevin Sharer, chairman and chief executive officer, and other members ...
... not have same impact, study finds , , MONDAY, April ... beverages can have a negative effect on the body,s ... increasing the risk of heart attack and stroke, a ... have that kind of impact, the study found. , ...
... SYK ) reported operating results for the quarter ended March ... , Net sales increased ... $1,601 million , Orthopaedic Implants ... reported) , MedSurg Equipment sales ...
... Environmental or therapeutic contact also led to poorer outcomes, ... Thyroid cancer patients who,ve previously been exposed to radiation ... patients, a new study finds. , Researchers at Mount ... who,d been exposed to radiation -- for example, in ...
Cached Medicine News:Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 2Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 3Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 4Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 2Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 3Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 4Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 5Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 6Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 7Health News:Amgen Announces Webcast of 2009 First Quarter Financial Results 2Health News:Stryker Operating Results for Quarter Ended March 31, 2009 2Health News:Stryker Operating Results for Quarter Ended March 31, 2009 3Health News:Stryker Operating Results for Quarter Ended March 31, 2009 4Health News:Stryker Operating Results for Quarter Ended March 31, 2009 5Health News:Stryker Operating Results for Quarter Ended March 31, 2009 6Health News:Stryker Operating Results for Quarter Ended March 31, 2009 7Health News:Stryker Operating Results for Quarter Ended March 31, 2009 8Health News:Radiation Exposure Linked to Aggressive Thyroid Cancers 2
... The Monarc Subfascial Hammock™ is ... female patients suffering from stress urinary ... by supporting the urethra during abdominal ... or laughing. Monarc's outside-to-in transobturator approach ...
... innovative architecture of the Uretex® ... and integrity for tension-free sling ... anchors securely to surrounding tissue ... alternate fixation devices, minimizing risk ...
Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...
NephroMax High Pressure Nephrostomy Balloon Catheter allows one-step, atraumatic dilatation of the nephrostomy tract....
Medicine Products: